5/23/2018: Aegle Therapeutics Corp. announced today that Shelley Hartman, the Company’s CEO, will present at the 2018 BIO International Convention at the Boston Convention and Exhibition Center in Boston, MA. The presentation will take place on Monday, June 4, 2018 at 4:15pm in Theater 1.
5/21/2018: Aegle Therapeutics Corp. announces the election of Matthew Vogelhuber to its Board of Directors. [Click]
5/15/2018: Aegle Therapeutics Corporation today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s first Investigational New Drug (IND) application to begin clinical trials in burn patients. Aegle expects to initiate a Phase 1/2a clinical trial of AGLE-102 for the treatment of severe burn patients in late 2018. [Click]
4/10/2018: Aegle Therapeutics researchers publish Dual mechanism of type VII collagen transfer by bone marrow mesenchymal stem cell extracellular vesicles to recessive dystrophic epidermolysis bullosa fibroblasts in Biochimie, April 10, 2108. [Click]
12/19/2017: Aegle announces the appointment of Dr. Robert Ryan, CEO of Innova Therapeutics, to its board of directors. [Click]
11/1/2017: Aegle announces the addition of Dr. Ian McNiece to our senior management team as Vice President of Research and Development.
3/1/2016: Aegle Therapeutics is selected for Springboard’s 2016 Health Innovation Hub.
2/1/2015: Aegle Therapeutics signs an exclusive license from the University of Miami (Miami, FL) for the rights to extracellular vesicle isolation technology and the use of extracellular vesicles isolated using the proprietary process for therapeutic and diagnostic indications.